GT Biopharma, Inc.

GTBPNASDAQ · Healthcare · Biotechnology

GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its propri…

$4.42-2.64%

报价 2026-11-06

市值

$5.6M

$2.1M

PE (TTM)

–

预期 PE (FY2026)

–

52 周区间距高点 -80.8%

$4.42$23.02

筛选结果

pipeline · 2026-11-06

Filter✗ 高增长✗ Cheap✗ GARP

excluded industry: Biotechnology

研究结论

还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。

去生成基本面报告 →

历史股价

加载中…

事件

0 条 · 随区间与图例筛选

该区间内无事件。

同行对比

FMP 同行列表 · 2026-05-16

公司	市值	今日	预期营收增速	毛利率	PE	EV/EBITDA	P/FCF
GTBPGT Biopharma, Inc.	$5.6M	-2.6%	-28.1%	0%	–	–	–
ARTLArtelo Biosciences, Inc.	$6.7M	-9.7%	–	0%	–	–	–
DRMADermata Therapeutics, Inc.	$3.8M	+0.3%	–	0%	–	–	–
REVBRevelation Biosciences, Inc.	$2.2M	+9.3%	–	0%	–	–	–
SLXNSilexion Therapeutics Ltd.	$60,838	+1.0%	–	0%	–	–	–
同行中位数	–	–	–	0%	–	–	–

研究全文

L2 基本面 memo

尚无基本面 memo

点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。

财务报表

暂无季度数据（首次研究运行后填充）。

研究材料

Filing 摘要

10-Q · 2026-05-150001493152-26-023346 S-1 · 2026-04-300001493152-26-020697 8-K · 2026-04-070001493152-26-015413 10-Q/A · 2026-03-060001493152-26-009127 10-Q/A · 2026-03-060001493152-26-009126

电话会纪要摘要

暂无纪要摘要。

我的笔记

AI 刷新不会修改

判断与复查· 可选：填复查日期后会进首页待办

加载中…

关键指标

其他估值

EV/EBITDA–

P/FCF–

P/S–

MC/GP–

PB2.43x

PEG0.00x

经营

营收 (TTM)$0

营收同比 (TTM)–

净利润 (TTM)$-22.1M

净利同比 (TTM)–

下一财年营收增速-28.1%

毛利率0%

经营利润率0%

净利率0%

FCF (TTM)$-14.4M

ROE-443.1%

ROIC-457.7%

资产负债

负债/权益0

流动比率2.61

Beta0.64

财务数据更新于 2026-10-27

分析师

EPS 超预期近 8 季 3 次 beat

+17.0

+43.3

-7.1

-18.8

+19.1

-118

-909

-37.5

2024-082026-05

内部人交易

近 180 天 · 仅公开市场买卖

无公开市场买入或卖出。

公司资料

GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I/II clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.

展开全文

CEO Michael Martin Breen

员工 1

IPO 2018-03-27

官网 StockAnalysis

数据截至 2026-10-27